血液スクリーニング市場 : 2028年までの世界予測

出版：MarketsandMarkets（マーケッツアンドマーケッツ）　出版年月：2023年10月

Blood Screening Market – Global Forecast to 2028

血液スクリーニング市場 : 製品 (試薬＆キット、機器、ソフトウェア)、テクノロジー [NAT、(リアルタイム PCR)、ELISA (化学発光免疫測定法)、迅速検査、ウェスタンブロット]、エンドユーザー (血液銀行、病院)、地域別 – 2028年までの世界予測
Blood Screening Market by Product (Reagent & Kits, Instrument, Software), Technology (NAT, (Real-Time PCR), ELISA (Chemiluminescence Immunoassay), Rapid Test, Western Blot), End User (Blood Bank, Hospital), & Region – Global Forecast to 2028

ページ数	253
図表数	266
種別	英文調査報告書
価格

お問合せ・ご注文　　価格・納期について

レポート概要レポート目次

Report Overview

The global blood screening market is projected to reach USD 3.4 billion by 2028 from USD 2.4 billion in 2023, at a CAGR of 7.2% during the forecast period. Growth in this market is mainly driven by the growing requirement for donated blood, the rising number of blood donations around the world, and the ever-increasing infectious diseases. However high prices of Blood screening instruments and kits along with scarcity in technicians is likely to hamper the growth of Blood screening market.

“The reagents & kits segment accounted for the highest growth rate in the blood screening market, by product & service, during the forecast period.”
The blood screening market is segmented into reagents & kits, instruments, and software & services based on product. In 2022, the reagents & kits segment accounted for the highest growth rate in the blood screening market. Market growth can largely be attributed to rising number of blood transfusions and blood donations. In addition, technological advancements in blood screening technologies and the increasing number of surgeries are stimulating the growth of this segment.

Blood Screening Market - Global Forecast to 2028 - ecosystem

“Blood banks segment accounted for the highest CAGR.”
Based on end users, the blood screening market is segmented into blood banks and hospitals. In 2022, the blood banks segment accounted for the highest growth rate. This can be attributed to the growing number of organ transplantation surgeries, and rising awareness about blood safety.

“Asia Pacific: The fastest-growing region blood screening market.”
The global blood screening market is divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The highest CAGR is anticipated to be recorded over the forecast period in the Asia Pacific region. The rising per capita income, the expansion of private hospitals into rural areas in various APAC countries, the rising geriatric population in several APAC countries (coupled with the rising prevalence of chronic disorders), and the presence of high-growth markets in the region, among other factors, all contribute to rising healthcare spending. The favorable regulatory climate and low labor costs in this region are also anticipated to fuel market growth.

Blood Screening Market - Global Forecast to 2028 - region

Breakdown of supply-side primary interviews, by company type, designation, and region:
• By Company Type: Tier 1 (40%), Tier 2 (30%), and Tier 3 (30%)
• By Designation: C-level (27%), Director-level (18%), and Others (55%)
• By Region: North America (51%), Europe (21%), Asia- Pacific (18%), Latin America (6%), and Middle East & Africa(4%)

Prominent companies include F. Hoffmann-La Roche Ltd. (Switzerland), Grifols (Spain), Abbott Laboratories, Inc. (US), Bio-Rad Laboratories, Inc. (US), Danaher (Beckman Coulter, Inc.) (US), bioMérieux (France), Hologic (US), Thermo Fisher Scientific, Inc. (US), Becton, Dickinson and Company (US), DiaSorin (Italy), Siemens Healthineers (Germany), QuidelOrtho Corporation (US), Merck KGaA (Germany), Revvity (Earlier known as PerkinElmer Inc.) (US), Bio-Techne Corporation (US), GFE (Germany), Trinity Biotech (Ireland), Mindray (China), Maccura Biotechnology Co., Ltd. (China), Immucor, Inc. (US), Cellabs (Australia), Abnova Corporation (Taiwan), Enzo Biochem, Inc. (US), J. Mitra & Co. Pvt. Ltd. (India) and Tulip Diagnostics (India).

Research Coverage
This research report categorizes the Blood screening market by products & service, technology, end user, and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the Blood screening market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements, new product & service launches, mergers and acquisitions, and recent developments associated with the Blood screening market. Competitive analysis of upcoming startups in the Blood screening market ecosystem is covered in this report.

Reasons to buy this report
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall blood screening market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:
• Analysis of key drivers (Increasing number of blood donations, rising infectious diseases and growing technological advancements), restraints (Alternative Technologies), opportunities (Increasing Demand from Emerging Economies in APAC, Increasing collaboration between businesses, industry associations, and government awareness), and challenges (High cost of blood screening products) influencing the growth of the blood screening market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the blood screening market
• Market Development: Comprehensive information about lucrative markets – the report analyses the blood screening market across varied regions.
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the blood screening market
• Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like F. Hoffmann-La Roche Ltd. (Switzerland), Grifols (Spain), Abbott Laboratories, Inc. (US), Bio-Rad Laboratories, Inc. (US), Danaher (Beckman Coulter, Inc.) (US), bioMérieux (France), among others in blood screening market

Table of Contents

1 INTRODUCTION 33

1.1 STUDY OBJECTIVES 33

1.2 MARKET DEFINITION 33

1.2.1 INCLUSIONS AND EXCLUSIONS 34

1.3 MARKET SCOPE 35

1.3.1 BLOOD SCREENING MARKET 35

1.3.2 REGIONS COVERED 36

1.4 YEARS CONSIDERED 36

1.5 CURRENCY CONSIDERED 37

1.6 LIMITATIONS 37

1.7 STAKEHOLDERS 37

1.8 SUMMARY OF CHANGES 37

1.9 RECESSION IMPACT 38

2 RESEARCH METHODOLOGY 39

2.1 RESEARCH DATA 39

2.2 RESEARCH APPROACH 39

FIGURE 1 BLOOD SCREENING MARKET: RESEARCH DESIGN METHODOLOGY 39

2.2.1 SECONDARY DATA 40

2.2.1.1 Key data from secondary sources 40

2.2.2 PRIMARY DATA 41

2.2.2.1 Primary sources 42

2.2.2.2 Key data from primary sources 42

2.2.2.3 Key industry insights 43

2.2.2.4 Breakdown of primary interviews 44

FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 44

FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 44

2.3 MARKET SIZE ESTIMATION 45

2.3.1 BOTTOM-UP APPROACH 45

2.3.1.1 Approach 1: Company revenue estimation approach 45

FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 45

2.3.1.2 Approach 2: Presentations of companies and primary interviews 46

2.3.1.3 Growth forecast 46

2.3.1.4 CAGR projections 46

FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 46

2.3.2 TOP-DOWN APPROACH 47

FIGURE 6 BLOOD SCREENING MARKET: TOP-DOWN APPROACH 47

2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 48

FIGURE 7 DATA TRIANGULATION METHODOLOGY 48

2.5 MARKET SHARE ANALYSIS 49

2.6 STUDY ASSUMPTIONS 49

2.7 GROWTH RATE ASSUMPTIONS 50

2.8 RISK ASSESSMENT 50

2.8.1 RISK ASSESSMENT ANALYSIS 50

2.9 RECESSION IMPACT ANALYSIS 50

3 EXECUTIVE SUMMARY 52

FIGURE 8 BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION) 52

FIGURE 9 BLOOD SCREENING MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION) 53

FIGURE 10 BLOOD SCREENING MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 53

FIGURE 11 BLOOD SCREENING MARKET, BY REGION, 2023 VS. 2028 (USD MILLION) 54

4 PREMIUM INSIGHTS 55

4.1 BLOOD SCREENING MARKET OVERVIEW 55

FIGURE 12 INCREASING NUMBER OF BLOOD DONATIONS TO DRIVE MARKET GROWTH DURING FORECAST PERIOD 55

4.2 BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 56

FIGURE 13 REAGENTS & KITS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 56

4.3 BLOOD SCREENING MARKET, BY TECHNOLOGY, 2023 VS. 2028 56

FIGURE 14 NUCLEIC ACID TESTS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 56

4.4 BLOOD SCREENING MARKET, BY END USER, 2023 VS. 2028 57

FIGURE 15 BLOOD BANKS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 57

4.5 BLOOD SCREENING MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES 57

FIGURE 16 ASIA PACIFIC REGION TO REGISTER HIGHEST GROWTH RATE FROM 2023 TO 2028 57

5 MARKET OVERVIEW 58

5.1 INTRODUCTION 58

5.2 MARKET DYNAMICS 58

FIGURE 17 BLOOD SCREENING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 58

5.2.1 DRIVERS 59

5.2.1.1 Increasing blood donations 59

5.2.1.2 Rising prevalence of infectious diseases 60

5.2.2 RESTRAINTS 60

5.2.2.1 High cost of blood screening technologies 60

5.2.3 OPPORTUNITIES 61

5.2.3.1 Rising technological advancements 61

5.2.3.2 High growth potential of emerging economies 61

5.2.4 CHALLENGES 62

5.2.4.1 Usage of low-sensitivity screening tests 62

5.2.4.2 Shortage of skilled laboratory technicians 62

5.3 PRICING ANALYSIS 63

5.3.1 PRICING MODEL ANALYSIS 63

TABLE 1 INDICATIVE PRICING ANALYSIS FOR BLOOD SCREENING PRODUCTS 63

5.3.2 AVERAGE SELLING PRICE TREND 63

TABLE 2 AVERAGE SELLING PRICE ANALYSIS OF BLOOD SCREENING PRODUCTS 63

5.3.3 AVERAGE SELLING PRICE OF BLOOD SCREENING PRODUCTS, BY KEY PLAYER 64

TABLE 3 AVERAGE SELLING PRICE OF BLOOD SCREENING PRODUCTS 64

5.4 PATENT ANALYSIS 65

5.4.1 PATENT ANALYSIS OF NUCLEIC ACID AMPLIFICATION TECHNOLOGIES 65

5.4.2 BLOOD SCREENING MARKET: LIST OF MAJOR PATENTS 66

5.5 VALUE CHAIN ANALYSIS 66

FIGURE 18 MAJOR VALUE ADDED DURING MANUFACTURING & ASSEMBLY PHASE 67

5.6 SUPPLY CHAIN ANALYSIS 67

FIGURE 19 BLOOD SCREENING MARKET: SUPPLY CHAIN ANALYSIS 68

5.7 ECOSYSTEM ANALYSIS 68

FIGURE 20 BLOOD SCREENING MARKET: ECOSYSTEM MAP 69

5.7.1 BLOOD SCREENING MARKET: ECOSYSTEM ROLE 69

5.8 PORTER’S FIVE FORCES ANALYSIS 70

TABLE 4 BLOOD SCREENING MARKET: PORTER’S FIVE FORCES ANALYSIS 70

5.8.1 THREAT OF NEW ENTRANTS 70

5.8.2 THREAT OF SUBSTITUTES 70

5.8.3 BARGAINING POWER OF BUYERS 70

5.8.4 BARGAINING POWER OF SUPPLIERS 70

5.8.5 INTENSITY OF COMPETITIVE RIVALRY 71

5.9 REGULATORY LANDSCAPE 71

TABLE 5 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 71

TABLE 6 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 71

TABLE 7 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 72

TABLE 8 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 72

5.9.1 NORTH AMERICA 72

5.9.1.1 US 72

5.9.1.2 Canada 72

5.9.2 EUROPE 73

TABLE 9 EUROPE: CLASSIFICATION OF DEVICES 73

5.9.3 ASIA PACIFIC 74

5.9.3.1 China 74

5.9.3.2 Japan 74

TABLE 10 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 74

5.9.3.3 India 74

5.9.4 LATIN AMERICA 74

5.9.4.1 Brazil 75

5.9.5 MIDDLE EAST 75

5.10 TRADE ANALYSIS 75

5.10.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS 75

TABLE 11 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION) 75

TABLE 12 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION) 76

5.11 TECHNOLOGY ANALYSIS 76

5.12 KEY CONFERENCES AND EVENTS 77

TABLE 13 BLOOD SCREENING MARKET: DETAILED LIST OF CONFERENCES AND EVENTS (2023 −2024) 77

5.13 PESTLE ANALYSIS 78

5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 79

5.14.1 REVENUE SHIFT IN BLOOD SCREENING MARKET 79

5.15 KEY STAKEHOLDERS AND BUYING CRITERIA 79

5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS 79

FIGURE 21 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR BLOOD SCREENING PRODUCTS 79

TABLE 14 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR BLOOD SCREENING PRODUCTS (%) 80

5.15.2 BUYING CRITERIA 80

FIGURE 22 KEY BUYING CRITERIA FOR BLOOD SCREENING PRODUCTS 80

TABLE 15 KEY BUYING CRITERIA, BY PRODUCT & SERVICE 80

5.16 CASE STUDY ANALYSIS 81

5.16.1 CASE STUDY 1: OPTIMIZATION OF HBSAG QUANTITATIVE ELISA 81

5.16.2 CASE STUDY 2: CLINICAL EFFICACY OF NAT WITH ELISA 81

6 BLOOD SCREENING MARKET, BY PRODUCT & SERVICE 82

6.1 INTRODUCTION 83

TABLE 16 BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 83

6.2 REAGENTS & KITS 83

TABLE 17 KEY PRODUCTS FOR REAGENTS & KITS 84

TABLE 18 BLOOD SCREENING MARKET FOR REAGENTS & KITS, BY REGION, 2021–2028 (USD MILLION) 84

TABLE 19 BLOOD SCREENING MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION) 85

6.2.1 NAT REAGENTS & KITS 85

6.2.1.1 High sensitivity to drive market 85

TABLE 20 KEY PRODUCTS FOR NAT REAGENTS & KITS 86

TABLE 21 BLOOD SCREENING MARKET FOR NAT REAGENTS & KITS, BY REGION, 2021–2028 (USD MILLION) 87

TABLE 22 BLOOD SCREENING MARKET FOR NAT REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION) 87

6.2.2 ELISA REAGENTS & KITS 87

6.2.2.1 Ease of use and cost-effectiveness to drive market 87

TABLE 23 KEY PRODUCTS FOR ELISA REAGENTS & KITS 89

TABLE 24 BLOOD SCREENING MARKET FOR ELISA REAGENTS & KITS, BY REGION, 2021–2028 (USD MILLION) 89

TABLE 25 BLOOD SCREENING MARKET FOR ELISA REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION) 90

6.2.3 OTHER REAGENTS & KITS 90

TABLE 26 KEY PRODUCTS FOR OTHER REAGENTS & KITS 90

TABLE 27 BLOOD SCREENING MARKET FOR OTHER REAGENTS & KITS, BY REGION, 2021–2028 (USD MILLION) 91

6.3 INSTRUMENTS 91

TABLE 28 KEY PRODUCTS FOR INSTRUMENTS 92

TABLE 29 BLOOD SCREENING MARKET FOR INSTRUMENTS, BY REGION, 2021–2028 (USD MILLION) 92

TABLE 30 BLOOD SCREENING MARKET FOR INSTRUMENTS, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 93

6.3.1 RENTAL PURCHASE 93

6.3.1.1 Reduced liability with limited financial losses to propel market 93

TABLE 31 BLOOD SCREENING MARKET FOR RENTAL PURCHASE INSTRUMENTS, BY REGION, 2021–2028 (USD MILLION) 93

6.3.2 OUTRIGHT PURCHASE 94

6.3.2.1 Availability of government support to drive market 94

TABLE 32 BLOOD SCREENING MARKET FOR OUTRIGHT PURCHASE INSTRUMENTS, BY REGION, 2021–2028 (USD MILLION) 94

6.4 SOFTWARE & SERVICES 94

6.4.1 RISING DEMAND ACROSS EMERGING ECONOMIES TO SUPPORT MARKET GROWTH 94

TABLE 33 KEY PRODUCTS FOR SOFTWARE & SERVICES 95

TABLE 34 BLOOD SCREENING MARKET FOR SOFTWARE & SERVICES, BY REGION, 2021–2028 (USD MILLION) 95

7 BLOOD SCREENING MARKET, BY TECHNOLOGY 96

7.1 INTRODUCTION 97

TABLE 35 BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 97

7.2 NUCLEIC ACID TESTS (NAT) 97

TABLE 36 KEY PRODUCTS IN NAT MARKET 98

TABLE 37 BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY REGION, 2021–2028 (USD MILLION) 99

TABLE 38 BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 99

7.2.1 TRANSCRIPTION-MEDIATED AMPLIFICATION (TMA) 99

7.2.1.1 High sensitivity to support market growth 99

TABLE 39 BLOOD SCREENING MARKET FOR TMA, BY REGION, 2021–2028 (USD MILLION) 100

7.2.2 REAL-TIME POLYMERASE CHAIN REACTION (RT-PCR) 100

7.2.2.1 Elimination of contamination risks to propel market 100

TABLE 40 BLOOD SCREENING MARKET FOR RT-PCR, BY REGION, 2021–2028 (USD MILLION) 101

7.3 SEROLOGY/IMMUNOASSAYS 101

TABLE 41 KEY PRODUCTS FOR SEROLOGY/IMMUNOASSAYS 101

TABLE 42 BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY REGION, 2021–2028 (USD MILLION) 102

TABLE 43 BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 102

7.3.1 CHEMILUMINESCENT IMMUNOASSAYS (CLIA) 103

7.3.1.1 Ultra-sensitive and automated features to drive market 103

TABLE 44 BLOOD SCREENING MARKET FOR CHEMILUMINESCENT IMMUNOASSAYS, BY REGION, 2021–2028 (USD MILLION) 103

7.3.2 FLUORESCENT IMMUNOASSAYS (FIA) 103

7.3.2.1 Rising demand for safe & stable reagents to propel market 103

TABLE 45 BLOOD SCREENING MARKET FOR FLUORESCENT IMMUNOASSAYS, BY REGION, 2021–2028 (USD MILLION) 104

7.3.3 COLORIMETRIC IMMUNOASSAYS/ELISA (CI/ELISA) 104

7.3.3.1 Qualitative and quantitative antigen measurement for blood serum to drive market 104

TABLE 46 BLOOD SCREENING MARKT FOR COLORIMETRIC IMMUNOASSAYS/ELISA, BY REGION, 2021–2028 (USD MILLION) 105

7.4 RAPID TESTS 105

7.4.1 HIGH EFFICIENCY IN POC DIAGNOSTICS TO PROPEL MARKET 105

TABLE 47 KEY PRODUCTS FOR RAPID TESTS 106

TABLE 48 BLOOD SCREENING MARKET FOR RAPID TESTS, BY REGION, 2021–2028 (USD MILLION) 106

7.5 WESTERN BLOT ASSAYS 106

7.5.1 ABILITY TO DETECT RETROVIRUS ANTIBODIES TO DRIVE MARKET 106

TABLE 49 KEY PRODUCTS FOR WESTERN BLOT ASSAYS 107

TABLE 50 BLOOD SCREENING MARKET FOR WESTERN BLOT ASSAYS, BY REGION, 2021–2028 (USD MILLION) 107

7.6 NEXT-GENERATION SEQUENCING (NGS) 108

7.6.1 EMERGING TECHNOLOGY FOR HIV TESTING TO SUPPORT MARKET GROWTH 108

TABLE 51 BLOOD SCREENING MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2021–2028 (USD MILLION) 108

8 BLOOD SCREENING MARKET, BY END USER 109

8.1 INTRODUCTION 110

TABLE 52 BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 110

8.2 BLOOD BANKS 110

8.2.1 RISING INCIDENCE OF CHRONIC DISEASES TO DRIVE MARKET 110

TABLE 53 BLOOD SCREENING MARKET FOR BLOOD BANKS, BY REGION, 2021–2028 (USD MILLION) 111

8.3 HOSPITALS 111

8.3.1 INCREASING SURGICAL PROCEDURES TO PROPEL MARKET 111

TABLE 54 BLOOD SCREENING MARKET FOR HOSPITALS, BY REGION, 2021–2028 (USD MILLION) 112

9 BLOOD SCREENING MARKET, BY REGION 113

9.1 INTRODUCTION 114

TABLE 55 BLOOD SCREENING MARKET, BY REGION, 2021–2028 (USD MILLION) 114

9.2 NORTH AMERICA 114

FIGURE 23 NORTH AMERICA: BLOOD SCREENING MARKET SNAPSHOT 115

TABLE 56 NORTH AMERICA: BLOOD SCREENING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 116

TABLE 57 NORTH AMERICA: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 116

TABLE 58 NORTH AMERICA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 116

TABLE 59 NORTH AMERICA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 117

TABLE 60 NORTH AMERICA: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 117

TABLE 61 NORTH AMERICA: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 118

TABLE 62 NORTH AMERICA: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 118

TABLE 63 NORTH AMERICA: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 119

9.2.1 NORTH AMERICA: RECESSION IMPACT 119

9.2.2 US 119

9.2.2.1 Increasing prevalence of HIV and chronic diseases to drive market 119

TABLE 64 US: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 120

TABLE 65 US: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 121

TABLE 66 US: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 121

TABLE 67 US: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 121

TABLE 68 US: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 122

TABLE 69 US: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 122

TABLE 70 US: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 122

9.2.3 CANADA 123

9.2.3.1 Rising volume of surgical procedures to drive market 123

TABLE 71 CANADA: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 123

TABLE 72 CANADA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 124

TABLE 73 CANADA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 124

TABLE 74 CANADA: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 124

TABLE 75 CANADA: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 125

TABLE 76 CANADA: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 125

TABLE 77 CANADA: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 125

9.3 EUROPE 126

TABLE 78 EUROPE: BLOOD SCREENING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 126

TABLE 79 EUROPE: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 127

TABLE 80 EUROPE: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 127

TABLE 81 EUROPE: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 127

TABLE 82 EUROPE: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 128

TABLE 83 EUROPE: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 128

TABLE 84 EUROPE: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 129

TABLE 85 EUROPE: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 129

9.3.1 EUROPE: RECESSION IMPACT 129

9.3.2 GERMANY 130

9.3.2.1 High incidence of cancer to drive market 130

TABLE 86 GERMANY: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 130

TABLE 87 GERMANY: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 131

TABLE 88 GERMANY: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 131

TABLE 89 GERMANY: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 131

TABLE 90 GERMANY: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 132

TABLE 91 GERMANY: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 132

TABLE 92 GERMANY: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 132

9.3.3 FRANCE 133

9.3.3.1 Growing cases of HIV to propel market 133

TABLE 93 FRANCE: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 133

TABLE 94 FRANCE: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 133

TABLE 95 FRANCE: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 134

TABLE 96 FRANCE: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 134

TABLE 97 FRANCE: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 134

TABLE 98 FRANCE: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 135

TABLE 99 FRANCE: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 135

9.3.4 UK 135

9.3.4.1 Favorable government support for infectious disease screening to drive market 135

TABLE 100 UK: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 136

TABLE 101 UK: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 136

TABLE 102 UK: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 137

TABLE 103 UK: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 137

TABLE 104 UK: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 137

TABLE 105 UK: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 138

TABLE 106 UK: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 138

9.3.5 ITALY 138

9.3.5.1 Growing number of blood donors to support market growth 138

TABLE 107 ITALY: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 139

TABLE 108 ITALY: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 139

TABLE 109 ITALY: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 139

TABLE 110 ITALY: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 140

TABLE 111 ITALY: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 140

TABLE 112 ITALY: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 141

TABLE 113 ITALY: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 141

9.3.6 SPAIN 141

9.3.6.1 Rising adoption of NAT technology to propel market 141

TABLE 114 SPAIN: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 142

TABLE 115 SPAIN: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 142

TABLE 116 SPAIN: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 142

TABLE 117 SPAIN: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 143

TABLE 118 SPAIN: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 143

TABLE 119 SPAIN: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 144

TABLE 120 SPAIN: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 144

9.3.7 REST OF EUROPE 144

TABLE 121 GDP EXPENDITURE ON HEALTHCARE, BY COUNTRY (%) 145

TABLE 122 REST OF EUROPE: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 145

TABLE 123 REST OF EUROPE: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 145

TABLE 124 REST OF EUROPE: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 146

TABLE 125 REST OF EUROPE: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 146

TABLE 126 REST OF EUROPE: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 146

TABLE 127 REST OF EUROPE: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 147

TABLE 128 REST OF EUROPE: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 147

9.4 ASIA PACIFIC 147

FIGURE 24 ASIA PACIFIC: BLOOD SCREENING MARKET SNAPSHOT 148

TABLE 129 ASIA PACIFIC: BLOOD SCREENING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 149

TABLE 130 ASIA PACIFIC: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 149

TABLE 131 ASIA PACIFIC: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 149

TABLE 132 ASIA PACIFIC: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 150

TABLE 133 ASIA PACIFIC: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 150

TABLE 134 ASIA PACIFIC: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 150

TABLE 135 ASIA PACIFIC: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 151

TABLE 136 ASIA PACIFIC: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 151

9.4.1 ASIA PACIFIC: RECESSION IMPACT 151

9.4.2 CHINA 152

9.4.2.1 High burden of infectious diseases to drive market 152

TABLE 137 CHINA: KEY MACROINDICATORS 152

TABLE 138 CHINA: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 153

TABLE 139 CHINA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 153

TABLE 140 CHINA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 153

TABLE 141 CHINA: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 154

TABLE 142 CHINA: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 154

TABLE 143 CHINA: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 155

TABLE 144 CHINA: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 155

9.4.3 JAPAN 155

9.4.3.1 Growing adoption of advanced blood screening technologies to drive market 155

TABLE 145 JAPAN: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 156

TABLE 146 JAPAN: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 156

TABLE 147 JAPAN: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 157

TABLE 148 JAPAN: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 157

TABLE 149 JAPAN: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 157

TABLE 150 JAPAN: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 158

TABLE 151 JAPAN: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 158

9.4.4 INDIA 158

9.4.4.1 Increasing road accidents to support market growth 158

TABLE 152 INDIA: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 159

TABLE 153 INDIA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 160

TABLE 154 INDIA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 160

TABLE 155 INDIA: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 160

TABLE 156 INDIA: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 161

TABLE 157 INDIA: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 161

TABLE 158 INDIA: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 161

9.4.5 AUSTRALIA 162

9.4.5.1 Increasing cases of leukemia to drive market 162

TABLE 159 AUSTRALIA: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 162

TABLE 160 AUSTRALIA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 162

TABLE 161 AUSTRALIA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 163

TABLE 162 AUSTRALIA: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 163

TABLE 163 AUSTRALIA: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 163

TABLE 164 AUSTRALIA: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 164

TABLE 165 AUSTRALIA: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 164

9.4.6 REST OF ASIA PACIFIC 164

TABLE 166 REST OF ASIA PACIFIC: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 165

TABLE 167 REST OF ASIA PACIFIC: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 165

TABLE 168 REST OF ASIA PACIFIC: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 166

TABLE 169 REST OF ASIA PACIFIC: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 166

TABLE 170 REST OF ASIA PACIFIC: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 166

TABLE 171 REST OF ASIA PACIFIC: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 167

TABLE 172 REST OF ASIA PACIFIC: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 167

9.5 LATIN AMERICA 167

TABLE 173 LATIN AMERICA: BLOOD SCREENING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 168

TABLE 174 LATIN AMERICA: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 168

TABLE 175 LATIN AMERICA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 169

TABLE 176 LATIN AMERICA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 169

TABLE 177 LATIN AMERICA: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 169

TABLE 178 LATIN AMERICA: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 170

TABLE 179 LATIN AMERICA: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 170

TABLE 180 LATIN AMERICA: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 170

9.5.1 LATIN AMERICA: RECESSION IMPACT 171

9.5.2 BRAZIL 171

9.5.2.1 Growing cancer burden to support market growth 171

TABLE 181 INCIDENCE OF CANCERS IN BRAZIL, 2020 VS. 2025 171

TABLE 182 BRAZIL: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 171

TABLE 183 BRAZIL: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 172

TABLE 184 BRAZIL: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 172

TABLE 185 BRAZIL: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 172

TABLE 186 BRAZIL: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 173

TABLE 187 BRAZIL: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 173

TABLE 188 BRAZIL: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 174

9.5.3 MEXICO 174

9.5.3.1 Rising blood donations to support market growth 174

TABLE 189 MEXICO: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 174

TABLE 190 MEXICO: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 175

TABLE 191 MEXICO: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 175

TABLE 192 MEXICO: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 175

TABLE 193 MEXICO: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 176

TABLE 194 MEXICO: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 176

TABLE 195 MEXICO: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 176

9.5.4 REST OF LATIN AMERICA 177

TABLE 196 REST OF LATIN AMERICA: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 177

TABLE 197 REST OF LATIN AMERICA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 177

TABLE 198 REST OF LATIN AMERICA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 178

TABLE 199 REST OF LATIN AMERICA: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 178

TABLE 200 REST OF LATIN AMERICA: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 178

TABLE 201 REST OF LATIN AMERICA: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 179

TABLE 202 REST OF LATIN AMERICA: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 179

9.6 MIDDLE EAST & AFRICA 179

9.6.1 RISING SURGICAL PROCEDURES DUE TO CHRONIC DISEASES TO FUEL MARKET 179

TABLE 203 MIDDLE EAST & AFRICA: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 180

TABLE 204 MIDDLE EAST & AFRICA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 181

TABLE 205 MIDDLE EAST & AFRICA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 181

TABLE 206 MIDDLE EAST & AFRICA: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 181

TABLE 207 MIDDLE EAST & AFRICA: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 182

TABLE 208 MIDDLE EAST & AFRICA: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 182

TABLE 209 MIDDLE EAST & AFRICA: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 183

9.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 183

10 COMPETITIVE LANDSCAPE 184

10.1 OVERVIEW 184

10.2 STRATEGIES OF KEY PLAYERS 184

10.2.1 BLOOD SCREENING MARKET: OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS 184

TABLE 210 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES 184

10.3 REVENUE SHARE ANALYSIS 186

FIGURE 25 REVENUE SHARE ANALYSIS OF LEADING PLAYERS IN BLOOD SCREENING MARKET 186

10.4 MARKET SHARE ANALYSIS 187

10.4.1 BLOOD SCREENING MARKET 187

FIGURE 26 MARKET SHARE ANALYSIS BY KEY PLAYER (2022) 187

TABLE 211 BLOOD SCREENING MARKET: INTENSITY OF COMPETITIVE RIVALRY 187

10.5 COMPANY EVALUATION MATRIX 188

10.5.1 LIST OF EVALUATED VENDORS 188

10.5.2 STARS 189

10.5.3 EMERGING LEADERS 189

10.5.4 PERVASIVE PLAYERS 189

10.5.5 PARTICIPANTS 189

FIGURE 27 BLOOD SCREENING MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2022) 190

10.6 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022) 191

10.6.1 PROGRESSIVE COMPANIES 191

10.6.2 STARTING BLOCKS 191

10.6.3 RESPONSIVE COMPANIES 191

10.6.4 DYNAMIC COMPANIES 191

FIGURE 28 BLOOD SCREENING MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022) 192

10.7 COMPETITIVE BENCHMARKING 193

10.7.1 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS 193

FIGURE 29 BLOOD SCREENING MARKET: PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS 193

TABLE 212 BLOOD SCREENING MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS 193

TABLE 213 BLOOD SCREENING MARKET: COMPANY PRODUCT & SERVICE FOOTPRINT ANALYSIS 194

TABLE 214 BLOOD SCREENING MARKET: COMPANY REGIONAL FOOTPRINT ANALYSIS 194

TABLE 215 BLOOD SCREENING MARKET: DETAILED LIST OF KEY STARTUPS/SMES 194

10.8 COMPETITIVE SCENARIO 195

10.8.1 PRODUCT LAUNCHES 195

TABLE 216 BLOOD SCREENING MARKET: KEY PRODUCT LAUNCHES & APPROVALS (JANUARY 2020−SEPTEMBER 2023) 195

10.8.2 DEALS 196

TABLE 217 BLOOD SCREENING MARKET: KEY DEALS (JANUARY 2020−SEPTEMBER 2023) 196

11 COMPANY PROFILES 198

11.1 KEY PLAYERS 198

(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*

11.1.1 F. HOFFMANN-LA ROCHE LTD. 198

TABLE 218 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW 198

FIGURE 30 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022) 199

11.1.2 GRIFOLS, S.A. 204

TABLE 219 GRIFOLS, S.A.: BUSINESS OVERVIEW 204

FIGURE 31 GRIFOLS S.A.: COMPANY SNAPSHOT (2022) 205

11.1.3 ABBOTT LABORATORIES 208

TABLE 220 ABBOTT LABORATORIES: BUSINESS OVERVIEW 208

FIGURE 32 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022) 209

11.1.4 BIO-RAD LABORATORIES, INC. 212

TABLE 221 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 212

FIGURE 33 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022) 213

11.1.5 DIASORIN 218

TABLE 222 DIASORIN: BUSINESS OVERVIEW 218

FIGURE 34 DIASORIN: COMPANY SNAPSHOT (2022) 219

11.1.6 BIOMÉRIEUX 223

TABLE 223 BIOMÉRIEUX: BUSINESS OVERVIEW 223

FIGURE 35 BIOMÉRIEUX: COMPANY SNAPSHOT (2022) 224

11.1.7 BD 226

TABLE 224 BD: BUSINESS OVERVIEW 226

FIGURE 36 BD: COMPANY SNAPSHOT (2022) 227

11.1.8 DANAHER (BECKMAN COULTER, INC.) 229

TABLE 225 DANAHER: BUSINESS OVERVIEW 229

FIGURE 37 DANAHER: COMPANY SNAPSHOT (2022) 230

11.1.9 HOLOGIC, INC. 232

TABLE 226 HOLOGIC, INC.: BUSINESS OVERVIEW 232

FIGURE 38 HOLOGIC, INC.: COMPANY SNAPSHOT (2022) 233

11.1.10 SIEMENS HEALTHINEERS AG 236

TABLE 227 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW 236

FIGURE 39 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022) 237

11.1.11 THERMO FISHER SCIENTIFIC, INC. 239

TABLE 228 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW 239

FIGURE 40 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022) 240

11.2 OTHER PLAYERS 243

11.2.1 ORTHO CLINICAL DIAGNOSTICS 243

11.2.2 MERCK KGAA 244

11.2.3 REVVITY (PART OF PERKINELMER INC.) 245

11.2.4 BIO-TECHNE 246

11.2.5 GFE 247

11.2.6 TRINITY BIOTECH 248

11.2.7 J. MITRA & CO. PVT. LTD. 249

11.2.8 MINDRAY 250

11.2.9 MACCURA BIOTECHNOLOGY CO., LTD. 251

11.2.10 IMMUCOR, INC. 252

11.2.11 CELLABS 252

11.2.12 ABNOVA CORPORATION 253

11.2.13 ENZO BIOCHEM, INC. 254

11.2.14 TULIP DIAGNOSTICS PVT. LTD. 254

*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

12 APPENDIX 255

12.1 DISCUSSION GUIDE 255

12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 259

12.3 CUSTOMIZATION OPTIONS 261

12.4 RELATED REPORTS 261

12.5 AUTHOR DETAILS 262

Disclaimer: MarketsandMarkets™ provides strategic analysis services to a select group of customers in response to orders. Our customers acknowledge when ordering that these strategic analysis services are solely for internal use and not for general publication or disclosure to any third party. MarketsandMarkets™ does not endorse any vendor, product, or service profiled in its publications. MarketsandMarkets’™ strategic analysis constitutes estimations and projections based on secondary and primary research and are therefore subject to variations. MarketsandMarkets™ disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness, for any particular purpose. MarketsandMarkets™ takes no responsibility for incorrect information supplied to it by manufacturers or users.

Trademarks, copyrights, and other forms of intellectual property belong to MarketsandMarkets™ or their respective owners and are protected by law. Under no circumstance may any of these be reproduced, copied, or circulated in any form, without the prior written approval of MarketsandMarkets™ or its owner—as the case may be. No part of this strategic analysis service may be given, lent, resold, or disclosed to any third party, without express permission from MarketsandMarkets™.

Reproduction and/or transmission in any form and by any means, including photocopying, mechanical, electronic, recording, or otherwise, without the permission of MarketsandMarkets™, is prohibited.

For information regarding permission, contact:

Tel: +1-888-600-6441

MarketsandMarkets™ is the world’s largest revenue impact company, serving over 7500 customers. 80% of top 2000 companies globally rely on us for identifying new high growth and niche revenue opportunities. In the face of constant technology innovation and market disruption, we help organizations plan and operationalize their future revenue mix decisions by identifying over 30,000 high growth opportunities ranging from $1B to $500B across 90+ industry trends and markets. Organizations choose MarketsandMarkets™ to stay ahead of the curve and accelerate their revenue decisions and implementations by 6 – 12 months, giving them a unique, first-mover advantage. Our revenue impact methodology provides quantified and actionable insights on converged, granular and connected market eco-systems that result from disruptive technologies and high-growth markets. We provide an extended lens on not only what will impact our client’s revenue but also what will impact their clients’ revenues, continually uncovering latent opportunities.

We work across all major B2B industries with C-level executives in functions such as Strategy, Marketing, Sales, R&D, Product, and M&A. MarketsandMarkets™ brings exclusive high-growth markets intelligence generated by over 850 SMEs and analysts along with its proprietary Revenue Impact platform (Knowledge Store).

All Rights Reserved. This document contains highly confidential information and is the sole property of MarketsandMarkets™. No part of it shall be circulated, copied, quoted, or otherwise reproduced without the prior written approval of MarketsandMarkets™.

TABLE OF CONTENTS